Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Octylonium bromide interacts competitively with the PAF receptor.

D Barone1, C A Maggi, P Baroldi

  • 1Istituto di Ricerche Biomediche A. Marxer, Ivrea, Italy.

Drugs Under Experimental and Clinical Research
|January 1, 1989
PubMed
Summary

Octylonium bromide competitively inhibits platelet-activating factor (PAF) receptor binding. This drug, like a known PAF antagonist, reduces PAF receptor affinity without altering the total number of binding sites.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Transient paraplegia due to subarachnoid haemorrhage following spinal anaesthesia.

Anaesthesia reports·2020
Same author

ALDH2 Activity Reduces Mitochondrial Oxygen Reserve Capacity in Endothelial Cells and Induces Senescence Properties.

Oxidative medicine and cellular longevity·2018
Same author

The use of radial symmetry to localize retinal landmarks.

Computerized medical imaging and graphics : the official journal of the Computerized Medical Imaging Society·2013
Same author

VAMPIRE: Vessel assessment and measurement platform for images of the REtina.

Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference·2012
Same author

EGFR signaling upregulates expression of microsomal prostaglandin E synthase-1 in cancer cells leading to enhanced tumorigenicity.

Oncogene·2011
Same author

Effect of intrathecal administration of ET-1, ET-3 and ET(16-21) on blood pressure and micturition reflex in anesthetized rats.

Neurochemistry international·2010

Area of Science:

  • Pharmacology
  • Biochemistry
  • Molecular Biology

Background:

  • Platelet-activating factor (PAF) is a potent lipid mediator involved in inflammatory and allergic responses.
  • Understanding the interaction of drugs with the PAF receptor is crucial for developing targeted therapies.

Purpose of the Study:

  • To elucidate the mechanism by which octylonium bromide interacts with the PAF receptor.
  • To determine if octylonium bromide acts as a competitive inhibitor of PAF binding.

Main Methods:

  • Saturation binding studies using radiolabeled 3H-PAF.
  • Competition assays with increasing concentrations of octylonium bromide and a known PAF antagonist (L 652,731).
  • Analysis of binding data using non-linear fitting and Scatchard transformation.

Related Experiment Videos

Main Results:

  • Both octylonium bromide and L 652,731 decreased the affinity (increased KD) of the 3H-PAF/PAF receptor complex.
  • Neither compound affected the maximum number of PAF binding sites (Bmax).
  • Octylonium bromide exhibited a concentration-dependent increase in KD, consistent with competitive inhibition.

Conclusions:

  • Octylonium bromide competitively inhibits the binding of 3H-PAF to its receptor on platelets.
  • The observed binding behavior suggests octylonium bromide functions as a PAF receptor antagonist.